1 Drug, 1 Mission: What Should Investors Expect for Greenwich Life Sciences?

Jia Jie Chen, The Motley Fool
·4 min read
1 Drug, 1 Mission: What Should Investors Expect for Greenwich Life Sciences?

The top-performing IPO of 2020 is a high-risk, high-reward opportunity, with one drug in its pipeline and one disease in its sights. Is it worth investing in now?